A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
An open label study to determine the efficacy and safety of SPARC1507
Advanced Biliary Tract Cancer
DRUG: SPARC1507|DRUG: Reference1507
Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1, 3 years and 6 months
Overall survival in subjects treated with SPARC1507 versus Investigators choice, 3 years and 6 months|Overall response rate in subjects treated with PICN versus Investigators choice, 3 years and 6 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 3 years and 6 months
Subjects with advanced Biliary tract carcinoma meeting the eligibility criteria will be randomized in this study.